Plasma preptin levels in patients with type 2 diabetes mellitus

UĞUR, Kader; HALİFEOĞLU, İhsan; KALAYCI, Hatice; YILMAZ, MUSA; KALAYCI, Mehmet

Plasma preptin levels in patients with type 2 diabetes mellitus

Mehmet KALAYCI, (Elazığ Fethi Sekin Şehir Hastanesi)

İhsan HALİFEOĞLU, (Fırat Üniversitesi)

Hatice KALAYCI, (Elazığ Fethi Sekin Şehir Hastanesi)

Kader UĞUR, (Fırat Üniversitesi)

Musa YILMAZ (Hitit Üniversitesi)

International Journal of Medical Biochemistry

20 2

Yıl: 2019 Cilt: 2 Sayı: 1 Sayfa Aralığı: 1 - 5 Metin Dili: İngilizce İndeks Tarihi: 08-04-2020

Plasma preptin levels in patients with type 2 diabetes mellitus

Öz:

Objectives: Diabetes mellitus (DM) is a chronic disease characterized by hyperglycemia, and the prevalence is rapidlyincreasing worldwide. Preptin is a novel molecule with a metabolic effect that is secreted from pancreatic beta cellsalong with insulin. There are currently few studies about preptin in patients with type 2 DM (T2DM). This study wasdesigned to observe differences in the plasma preptin level in patients with T2DM in comparison with a control group.Methods: The study included 82 patients with T2DM (mean age: 49.00±5.97 years; 42 females, 40 males) and 65 healthyindividuals (mean age: 41.98±5.62 years; 31 females, 34 males). The patients with T2DM were divided into 2 groups:those newly diagnosed and those previously diagnosed and in treatment. The previously diagnosed group was furtherseparated into 2 groups based on their glycated hemoglobin (HbA1c) level: a well-controlled DM (HbA1C value <7%)group and a poorly controlled DM (HbA1C value >7%) group. The chemistry parameters were analyzed with an Advia1800 analyzer (Siemens Healthineers, Erlangen, Germany), and hormonal parameters were analyzed with an Immulite2000 analyzer (Siemens Healthineers, Erlangen, Germany). Plasma preptin levels were measured using the enzymelinkedimmunosorbent assay method.Results: Patients with newly or previously diagnosed T2DM had significantly higher glucose, HbA1c, insulin, homeostaticmodel assessment of insulin resistance (HOMA-IR), total cholesterol, triglyceride, low-density lipoprotein cholesterol,and preptin values (p<0.001 for each), and significantly lower high-density lipoprotein cholesterol levels comparedwith the control group (p<0.001). The preptin level demonstrated a positive correlation with insulin, HOMA-IR,HbA1c, and glucose levels (for control group: r=0.452-p=0.000, r=0.472-p=0.000, r=0.389-p=0.001, r=0.286-p=0.021,respectively; for T2DM group: r=0.484-p=0.000, r=0.544-p=0.000, r=0.288-p=0.009, r=0.236-p=0.033, respectively).Conclusion: The observed correlation between preptin level and DM a suggests that this peptide may have a possiblerole in the pathogenesis of DM, which may be particularly valuable, given that DM is a major public health problem.

Anahtar Kelime:

Konular: Biyoteknoloji ve Uygulamalı Mikrobiyoloji Biyokimya ve Moleküler Biyoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41:S13–27.
2. International Diabetes Federation. IDF Diabetes Atlas. 8th edition. Brussels: International Diabetes Federation; 2017.
3. Akın S, Erdem ME, Kazan S, Aliustaoğlu M. The relationship between helicobacter pylori infection and glycemic regulation in type 2 diabetic patients. Nobel Med 2014;10:32–5.
4. Buchanan CM, Phillips AR, Cooper GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 2001;360:431–9.
5. Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides 2014;56:94–110.
6. Cheng KC, Li YX, Asakawa A, Ushikai M, Kato I, Sato Y, et al. Characterization of preptin-induced insulin secretion in pancreatic β-cells. J Endocrinol 2012;215:43–9.
7. Ismayilnajadteymurabadi H, Konukoglu D. The relationship between preptin, Forkhead box protein O1 and mechanistic target of rapamycin levels in prediabetic patients. J Biol Regul Homeost Agents 2017; 31: 399–405.
8. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41:S55–64.
9. Powers AC. Diabetes Mellitus. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 18th edition USA: McGraw-Hill; 2012.
10. Lee JJ, Beretvas SN, Freeland-Graves JH. Abdominal Adiposity Distribution in Diabetic/Prediabetic and Nondiabetic Populations: A Meta-Analysis. J Obes 2014;2014:697264.
11. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: Implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med 2013;34:1–11.
12. Yang G, Li L, Chen W, Liu H, Boden G, Li K. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Ann Med 2009;41:52–6.
13. Aslan M, Celik O, Karsavuran N, Celik N, Dogan DG, Botan E, et al. Maternal serum and cord blood preptin levels in gestational diabetes mellitus. J Perinatol 2011;31:350–5.
14. Mierzwicka A, Kuliczkowska-Plaksej J, Kolačkov K, Bolanowski M. Preptin in women with polycystic ovary syndrome. Gynecol Endocrinol 2018;27:1–6.
15. Celik O, Celik N, Hascalik S, Sahin I, Aydin S, Ozerol E. An appraisal of serum preptin levels in PCOS. Fertil Steril 2011;95:314–6.

APA	KALAYCI M, HALİFEOĞLU İ, KALAYCI H, UĞUR K, YILMAZ M (2019). Plasma preptin levels in patients with type 2 diabetes mellitus. , 1 - 5.
Chicago	KALAYCI Mehmet,HALİFEOĞLU İhsan,KALAYCI Hatice,UĞUR Kader,YILMAZ MUSA Plasma preptin levels in patients with type 2 diabetes mellitus. (2019): 1 - 5.
MLA	KALAYCI Mehmet,HALİFEOĞLU İhsan,KALAYCI Hatice,UĞUR Kader,YILMAZ MUSA Plasma preptin levels in patients with type 2 diabetes mellitus. , 2019, ss.1 - 5.
AMA	KALAYCI M,HALİFEOĞLU İ,KALAYCI H,UĞUR K,YILMAZ M Plasma preptin levels in patients with type 2 diabetes mellitus. . 2019; 1 - 5.
Vancouver	KALAYCI M,HALİFEOĞLU İ,KALAYCI H,UĞUR K,YILMAZ M Plasma preptin levels in patients with type 2 diabetes mellitus. . 2019; 1 - 5.
IEEE	KALAYCI M,HALİFEOĞLU İ,KALAYCI H,UĞUR K,YILMAZ M "Plasma preptin levels in patients with type 2 diabetes mellitus." , ss.1 - 5, 2019.
ISNAD	KALAYCI, Mehmet vd. "Plasma preptin levels in patients with type 2 diabetes mellitus". (2019), 1-5.

APA	KALAYCI M, HALİFEOĞLU İ, KALAYCI H, UĞUR K, YILMAZ M (2019). Plasma preptin levels in patients with type 2 diabetes mellitus. International Journal of Medical Biochemistry, 2(1), 1 - 5.
Chicago	KALAYCI Mehmet,HALİFEOĞLU İhsan,KALAYCI Hatice,UĞUR Kader,YILMAZ MUSA Plasma preptin levels in patients with type 2 diabetes mellitus. International Journal of Medical Biochemistry 2, no.1 (2019): 1 - 5.
MLA	KALAYCI Mehmet,HALİFEOĞLU İhsan,KALAYCI Hatice,UĞUR Kader,YILMAZ MUSA Plasma preptin levels in patients with type 2 diabetes mellitus. International Journal of Medical Biochemistry, vol.2, no.1, 2019, ss.1 - 5.
AMA	KALAYCI M,HALİFEOĞLU İ,KALAYCI H,UĞUR K,YILMAZ M Plasma preptin levels in patients with type 2 diabetes mellitus. International Journal of Medical Biochemistry. 2019; 2(1): 1 - 5.
Vancouver	KALAYCI M,HALİFEOĞLU İ,KALAYCI H,UĞUR K,YILMAZ M Plasma preptin levels in patients with type 2 diabetes mellitus. International Journal of Medical Biochemistry. 2019; 2(1): 1 - 5.
IEEE	KALAYCI M,HALİFEOĞLU İ,KALAYCI H,UĞUR K,YILMAZ M "Plasma preptin levels in patients with type 2 diabetes mellitus." International Journal of Medical Biochemistry, 2, ss.1 - 5, 2019.
ISNAD	KALAYCI, Mehmet vd. "Plasma preptin levels in patients with type 2 diabetes mellitus". International Journal of Medical Biochemistry 2/1 (2019), 1-5.